Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice

Journal Article · Fri Apr 17 00:00:00 EDT 2009 · Biochemical and Biophysical Research Communications

DOI:https://doi.org/10.1016/J.BBRC.2009.02.075· OSTI ID:22199651

Fu, Yuanhui ^[1]; He, Jinsheng ^[2]; Zheng, Xianxian ^[3]; Wu, Qiang ^[4]; Zhang, Mei; Wang, Xiaobo ^[3]; Wang, Yan ^[4]; Xie, Can; Tang, Qian; Wei, Wei ^[3]; Wang, Min; Song, Jingdong; Qu, Jianguo ^[1]; Zhang, Ying; Wang, Xin ^[2]; Hong, Tao ^[1]

---

1. Institute of Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052 (China)
2. College of Life Sciences and Bioengineering, Beijing Jiaotong University, 3 Shangyuan Residence, Haidian District, Beijing, 100044 (China)
3. Department of Immunology, Anhui Medical University, Hefei, Anhui, 230032 (China)
4. Department of Pathology, Anhui Medical University, Hefei, Anhui, 230032 (China)

Human respiratory syncytial virus (RSV) is a serious pediatric pathogen of the lower respiratory tract worldwide. There is currently no clinically approved vaccine against RSV infection. Recently, it has been shown that a replication-deficient first generation adenoviral vector (FGAd), which encodes modified RSV attachment glycoprotein (G), elicits long-term protective immunity against RSV infection in mice. The major problem in developing such a vaccine is that G protein lacks MHC-I-restricted epitopes. However, RSV fusion glycoprotein (F) is a major cytotoxic T-lymphocyte epitope in humans and mice, therefore, an FGAd-encoding F (FGAd-F) was constructed and evaluated for its potential as an RSV vaccine in a murine model. Intranasal (i.n.) immunization with FGAd-F generated serum IgG, bronchoalveolar lavage secretory IgA, and RSV-specific CD8+ T-cell responses in BALB/c mice, with characteristic balanced or mixed Th1/Th2 CD4+ T-cell responses. Serum IgG was significantly elevated after boosting with i.n. FGAd-F. Upon challenge, i.n. immunization with FGAd-F displayed an effective protective role against RSV infection. These results demonstrate FGAd-F is able to induce effective protective immunity and is a promising vaccine regimen against RSV infection.

• OSTI ID: 22199651
• Journal Information: Biochemical and Biophysical Research Communications, Vol. 381, Issue 4; Other Information: Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
• Country of Publication: United States
• Language: English

Related Subjects

60 APPLIED LIFE SCIENCES
GLYCOPROTEINS
GTP-ASES
IMMUNITY
LAVAGE
LYMPHOCYTES
MICE
PATHOGENS
PEDIATRICS
VACCINES
VIRUSES